Expected FDA approval of transcatheter aortic valve replacement devices, already approved in Europe, would set off a boom in such devices over the next few years, according to a news release by the Millennium Research Group.
By 2015, transcatheter aortic valve replacement devices would make up almost 12 percent of all U.S. heart valve procedures. Such replacements are expected to contribute to a 6 percent average annual growth in U.S. heart valve procedures through 2015.
Of the three current trials on such devices, the PARTNER trial for Edwards Lifesciences' SAPIEN valve is the most advanced. In Sept. 2010, Edwards Lifesciences released preliminary findings showing that the device was superior to standard therapy in reducing patient mortality.
Read the Millennium Research Group release on heart valve procedures.
Related Articles on Aortic Valve Repair:
5 Ways to Improve Anesthesia Quality in Surgery Centers
Rhode Island Hospital Anesthesiologist Found Liable for $500K in Malpractice Case